| 
          NCCN Guidelines® Insights - Management of Immunotherapy-Related Toxicities, Version 2.2024         | 
              
          1.00         | 
              
          11/10/2024 - 12:00am to 11/10/2025 - 12:00am         | 
          
      
              | 
          Recorded Presentation from the NCCN Pharmacy Updates: Chemoimmunotherapy Updates in Advanced/Metastatic Non-Small Cell Lung Cancer         | 
              
          1.00         | 
              
          11/12/2024 - 12:00am to 11/12/2025 - 12:00am         | 
          
      
              | 
          Archived NCCN Tumor Boards: Multidisciplinary Management of Head and Neck Cancers         | 
              
          1.00         | 
              
          11/26/2024 - 12:00am to 11/26/2025 - 12:00am         | 
          
      
              | 
          Archived NCCN Tumor Boards: New Approaches to Treatment of Bladder Cancer         | 
              
          1.00         | 
              
          11/26/2024 - 12:00am to 11/26/2025 - 12:00am         | 
          
      
              | 
          Recorded Presentation from the NCCN Pharmacy Updates: Maintenance Strategies in the Management of Acute Myeloid Leukemia         | 
              
          1.00         | 
              
          11/26/2024 - 12:00am to 11/26/2025 - 12:00am         | 
          
      
              | 
          What is Optimal First-Line Management of Advanced Classic Hodgkin Lymphoma?         | 
              
          0.75         | 
              
          12/01/2024 - 12:00am to 12/01/2025 - 12:00am         | 
          
      
              | 
          Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Updates in Prognosis and Treatment         | 
              
          1.00         | 
              
          12/01/2024 - 12:00am to 12/01/2025 - 12:00am         | 
          
      
              | 
          Diffuse Large B-Cell Lymphoma: Sequencing Therapy for Relapsed/Refractory Disease         | 
              
          0.50         | 
              
          12/01/2024 - 12:00am to 12/01/2025 - 12:00am         | 
          
      
              | 
          Debate: Is the Addition of Polatuzumab Vedotin the New Standard First-Line Therapy for Diffuse Large B-Cell Lymphoma?         | 
              
          0.75         | 
              
          12/01/2024 - 12:00am to 12/01/2025 - 12:00am         | 
          
      
              | 
          Managing Post-Treatment Complications for Multiple Myeloma and Acute Lymphocytic Leukemia         | 
              
          1.00         | 
              
          12/01/2024 - 12:00am to 12/01/2025 - 12:00am         | 
          
      
              | 
          Management of Multiple Myeloma: Smoldering, Newly Diagnosed, and Relapsed/Refractory Disease         | 
              
          2.25         | 
              
          12/01/2024 - 12:00am to 12/01/2025 - 12:00am         | 
          
      
              | 
          Myelodysplastic Syndromes: Treatment Updates and Emerging Data         | 
              
          0.50         | 
              
          12/01/2024 - 12:00am to 12/01/2025 - 12:00am         | 
          
      
              | 
          Review of Oral Targeted Therapies in Acute Myeloid Leukemia         | 
              
          0.75         | 
              
          12/01/2024 - 12:00am to 12/01/2025 - 12:00am         | 
          
      
              | 
          Managing Earlier Integration of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia         | 
              
          0.75         | 
              
          12/01/2024 - 12:00am to 12/01/2025 - 12:00am         | 
          
      
              | 
          Diagnosis and Management of Blastic Plasmacytoid Dendritic Cell Neoplasm         | 
              
          0.50         | 
              
          12/01/2024 - 12:00am to 12/01/2025 - 12:00am         |